Most Popular Stories
- Competitor hospitals form joint cardiology physician practice
- Arizona becomes first state to drop children's health program
- Bill opposing health insurance mandate signed by Idaho governor
- Humana slammed after posting 65 percent increase in third quarter profits
- Health reform could cut deficit by $138B, CBO says
- State high court removes hospital's property tax exemption
Featured Jobs
-
Interventional Radiology Job in Hawaii
StaffPointe, LLC - confidential, HI -
Internal Medicine Job in Washington
StaffPointe, LLC - Seattle, WA -
Dir of Risk Management for Texas
StaffPointe, LLC - east, TX -
Invasive Cardiologist Job in Mississippi
StaffPointe, LLC - south, MS -
Internal Medicine Job in Oregon
StaffPointe, LLC - various locations, OR
Events
- Web & ACTION: Effective Crisis Management of Serious Clinical Events
March 31, 2010 - 6th Ann. World Health Care Congress Europe
19-20 May — Brussels, Belgium - New IHI Seminar: How Market Leaders Outpace the Competition
April 12-13, 2010 — Scottsdale, Arizona - Sensors Expo & Conference
June 7-9, 2010 — Rosemont, IL
Paid Research Reports
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
- Pipeline and Commercial Insight: Supportive Care in Oncology
- Mapping the Healthcare Landscape Bringing pharmaceuticals into focus
- The Gastrointestinal Market Outlook To 2014: Market dynamics, competitive landscape, emerging therapies
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
SPOTLIGHT: Study: Last-minute drug approvals less safe
March 27, 2008 — 7:59am ET
When FDA reviewers cram, do they perform poorly on the test? A new study concludes that yes, when drugs are approved right on deadline, they're more likely to cause safety problems later. The Harvard analysis, published in this week's New England Journal of Medicine, concludes that drugs approved in the two months leading up to the deadline are four to five times more likely to be withdrawn or require serious safety warnings. Report
SHARE WITH:
Related Stories
- Hospital night shifts severely lacking
- ALSO NOTED: U of Miami suffers massive patient data loss; Loyola U sets $1B strategic plan; and much more...
- Avandia gets black-box warning
- Direct-to-consumer pharma ads questioned
- FTC: Pharmas cut 14 deals to delay generic sales in '07
- ALSO NOTED: Salmonella on Discovery shuttle is first step in biotech space program; After initial shock, providers adjusting to
- Did Glaxo conceal Paxil users' risk of suicide?
- SPOTLIGHT: Revised study still finds that FDA approval rush may cause harm
- Study: Drugs may do as well as an angioplasty
- FDA control of tobacco approved by Senate
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map | List in Marketplace | Supplier MarketplaceTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2010 FierceMarkets. All rights reserved. |
![]() |





